Tenaya Therapeutics (NASDAQ:TNYA) Posts Earnings Results, Misses Expectations By $12.73 EPS

Tenaya Therapeutics (NASDAQ:TNYA) announced its quarterly earnings results on Wednesday. The company reported ($13.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($12.73), MarketWatch Earnings reports.

TNYA opened at $24.79 on Friday. Tenaya Therapeutics has a 12 month low of $15.35 and a 12 month high of $28.72.

A number of brokerages have recently weighed in on TNYA. Chardan Capital began coverage on Tenaya Therapeutics in a research report on Tuesday, August 24th. They set a “buy” rating and a $37.00 price target on the stock. Morgan Stanley began coverage on Tenaya Therapeutics in a research report on Tuesday, August 24th. They set an “overweight” rating and a $31.00 price target on the stock. Piper Sandler began coverage on Tenaya Therapeutics in a research report on Tuesday, August 24th. They issued an “overweight” rating and a $40.00 target price on the stock. Finally, Cowen began coverage on Tenaya Therapeutics in a research report on Tuesday, August 24th. They issued an “outperform” rating on the stock.

About Tenaya Therapeutics

Tenaya Therapeutics Inc is a biotechnology company. It discovers, develop and deliver curative therapies which address the underlying causes of heart disease. The company’s product platform consist Gene Therapy, Cellular Regeneration and Precision Medicine. Tenaya Therapeutics Inc is based in SOUTH SAN FRANCISCO, Calif.

Read More: What are benefits of a growth and income fund?

Receive News & Ratings for Tenaya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenaya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.